The Law Firm of Weiss & Lurie Investigates the Acquisition of Genoptix, Inc.
24 Enero 2011 - 3:58PM
Business Wire
Weiss & Lurie, a national class action and shareholder
rights law firm with offices in New York City and Los Angeles, is
investigating possible breaches of fiduciary duty and other
violations of law by members of the Board of Directors of
Genoptix, Inc. (NASDAQ: GXDX) arising from the proposed
acquisition of Genoptix by Novartis AG (NYSE: NVS).
Under the terms of the tender offer, shareholders will receive
$25.00 in cash for each share of Genoptix common stock. The
transaction is expected to close within the first half of 2011.
Weiss & Lurie is investigating whether Genoptix’s Board
acted in the best interests of shareholders in approving the
transaction and whether the Board properly sought to maximize
shareholder value. Each of Genoptix’ directors and executive
officers has agreed to tender their shares in the offer. Of
particular concern is that, as recently June 2010, Genoptix stock
traded above the $25.00 per share offered. Indeed, Genoptix stock
traded at a high of $39.00 per share in April and May 2010. At
least one analyst had set the target price of Genoptix stock at
$28.00 per share in December 2010, prior to the announcement of the
proposed transaction.
If you own Genoptix shares and would like more information about
your rights as a shareholder or additional information concerning
our investigation, please contact Julia J. Sun either by email at
infony@weisslurie.com or by telephone at (888) 593-4771.
Weiss & Lurie has litigated hundreds of stockholder class
and derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for defrauded
institutions and individuals and obtained important corporate
governance in these cases. If you have information or would like
legal advice concerning possible corporate wrongdoing (such as
insider trading, waste of corporate assets, accounting fraud, or
issuing materially misleading press releases or SEC filings),
consumer fraud (such as false advertising, defective products, or
other deceptive business practices), or anti-trust violations,
please email us at infony@weisslurie.com or fill out the form on
our website, http://www.weisslurie.com/contact/report_fraud/.
Attorney Advertising. Past results do not guarantee a similar
outcome.
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Genoptix, Inc. (MM) (NASDAQ): 0 recent articles
Más de Weiss & Lurie Artículos de Noticias